Orfiril (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril, is an anticonvulsant presented as a solid oral dosage form for systemic use. It is employed in the management of seizure disorders and is prescribed for both adult and pediatric patients. GNH USA supplies Orfiril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orfiril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril is a broad‑spectrum anticonvulsant that stabilises neuronal excitability in several seizure types.

- Epilepsy: reduces the frequency and severity of generalized tonic‑clonic seizures. - Absence seizures: helps control brief staring episodes characteristic of typical absence seizures. - Myoclonic seizures: diminishes the occurrence of sudden, brief muscle jerks. - Bipolar disorder (off‑label): may be used as a mood stabiliser in treatment‑resistant cases. - Migraine prophylaxis (off‑label): - Migraine